Evia/Entovis HF-T Master Study
Launched by BIOTRONIK SE & CO. KG · Mar 6, 2012
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Standard indication for CRT therapy
- • Legal capacity and ability to consent
- • Signed patient informed consent
- Exclusion Criteria:
- • Contraindication for CRT therapy
- • ICD indication
- • Age \< 18 years
- • Pregnant or breast-feeding woman
- • Cardiac surgery planned within the next 6 months
- • Life expectancy of less than 6 months
- • Participating in another clinical study of an investigational cardiac drug or device
About Biotronik Se & Co. Kg
Biotronik SE & Co. KG is a global leader in the development of innovative medical technology, specializing in cardiovascular and endovascular solutions. With a strong commitment to enhancing patient outcomes, the company focuses on advanced therapies and devices, including implantable cardioverter-defibrillators, cardiac resynchronization therapy, and vascular interventions. Biotronik's rigorous research and development initiatives, coupled with its dedication to clinical excellence, position the company at the forefront of medical advancement, striving to improve quality of life for patients worldwide. Through strategic partnerships and a robust clinical trial portfolio, Biotronik continues to drive innovation and set new standards in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Budapest, , Hungary
Budapest, , Hungary
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials